<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01182376</url>
  </required_header>
  <id_info>
    <org_study_id>IRB_00040931</org_study_id>
    <nct_id>NCT01182376</nct_id>
  </id_info>
  <brief_title>SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI</brief_title>
  <acronym>SOAR</acronym>
  <official_title>SOAR: Study Observing Antiarrhythmic Remodelling Using LGE-MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate how dronedarone (Multaq®) may aid in
      the slowing of progression of left atrial and ventricular fibrosis in patients with atrial
      fibrillation as assessed by late gadolinium enhanced magnetic resonance imaging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND AND INTRODUCTION:

      Atrial fibrillation (AF) arises as a result of a complex interaction between triggers,
      perpetuators and substrate. As early as 1995, Morillo et al have demonstrated that AF is
      associated with ultrastructural changes in myocytes. In animal models, alterations in
      myocytes after sustained AF resemble those of myocardial hybernation with a phenotypical
      adaptation towards a more fetal stage. Ultimately, these structural changes would lead to
      Calcium overload and metabolic stress, similar changes have been observed in humans. However,
      in humans, atrial dilatation and degenerative changes have been observed. Interstitial
      fibrosis (caused by deposits of collagen and fibronectin) is the prime cause of structural
      remodeling in left atrium (Boldt et al., 2004). It has been well established that fibrosis is
      a confounding clinical factor in causing AF (Kostin et al., 2002). But AF itself promotes
      fibrosis, which in turn leads to increased conduction heterogeneity within the atrial
      substrate resulting in further progression of AF (Everett,and Olgin, 2007).

      The recent introduction of Late Gadolinium enhancement magnetic resonance imaging (LGE-MRI)
      sequence now allows for non-invasive assessment of the location and extent of arrhythmia
      related fibrosis.

      Contrast enhancement occurs as a result of altered washout kinetics of gadolinium relative to
      normal surrounding tissue, which may reflect increased fibrosis or tissue remodeling of the
      myocardium. Our group has demonstrated the feasibility of a new LGE-MRI acquisition and
      processing protocol to detect fibrosis in the LA.

      To date, no controlled trials evaluating the effect of antiarrhythmic drugs (AAD) and
      regression of left atrial fibrosis as assessed by LGE-MRI has been performed. We propose to
      use LGE-MRI to evaluate the effects of dronedarone vs. placebo on atrial and ventricular
      fibrosis. It has been shown that the success of catheter ablation procedure (which has been
      shown to be superior in terms of maintaining sinus rhythm in AF patients when compared to
      anti-arrhythmic drugs) is dependent upon the extent of fibrosis (Akoum et al., in prep). In
      AF patients with greater than 35% enhancement (percent left atrial fibrosis), the success of
      catheter ablation in reducing AF recurrence is greatly reduced. Hence for these patients, a
      drug that can control the progression of fibrosis and simultaneously provide respite from AF
      recurrence would be an extremely desirable prescription.

      Multaq® is the chosen drug in this study because clinical trials (Hohnloser et al., 2009)
      have shown that it has the potential to reduce incidence of hospitalizations due to
      cardiovascular events by 25.5% and death in AF patients by 45%. We acknowledge the
      information that Dronedarone may be more prone to AF recurrence, however, it has a better
      safety profile with regards to thyroid and neurologic events and does not interfere with oral
      anticoagulants (Le Heuzey et al., 2010), which make dronedarone a more preferred
      antiarrhythmic drug to be used for this study. Furthermore, in patients who took dronedarone
      post cardioversion procedure to revert arrhythmia back to normal sinus rhythm (NSR),
      dronedarone has been shown to decrease AF recurrences (Le Heuzey et al., 2010).

      OBJECTIVES:

      Primary:

      The primary objective of this study is to demonstrate how dronedarone may aid in the
      regression or slowing of progression of left atrial and ventricular fibrosis in patients with
      atrial fibrillation as assessed by LGE-MRI, using longitudinal data from a double-blinded,
      prospective study of patients diagnosed with atrial fibrillation over a twelve month follow
      up period.

      Secondary:

        -  To study the effects of dronedarone in global parameters of myocardial remodeling such
           as right and left atrial volumes and right and left ventricular volumes.

        -  To study correlation between AF burden expressed as percentage of AF measured by an
           8-day Holter Monitoring at three, six and twelve months post initiation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LA Fibrosis</measure>
    <time_frame>baseline, 1 year</time_frame>
    <description>The change in left atrial fibrosis percentage, as measured on a scale, using MRI imaging, from baseline to the end of treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Half of the patients will be assigned placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multaq® (dronedarone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half of the patients will be prescribed dronedarone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dronedarone</intervention_name>
    <description>Dronedarone will be prescribed by the patient's team according to established guidelines.</description>
    <arm_group_label>Multaq® (dronedarone)</arm_group_label>
    <other_name>Multaq®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered by the patient's team according to established guidelines.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients age 18 and older

          -  Must carry a diagnosis of Paroxysmal Atrial Fibrillation for 1 months or longer prior
             to being enrolled.

          -  AAD: Multaq® (dronedarone) candidate

          -  Patients have given informed consent

        Exclusion Criteria:

          -  Patients who are unavailable to continue follow-up at the University of Utah
             outpatient clinic.

          -  Patients weighing &gt;200 lbs (MR image efficacy decreases due to density)

          -  Prior RF Ablation treatment for atrial fibrillation

          -  Severe renal failure manifested by a chronic GFR of &lt; 30 mL/min, or acute renal
             failure regardless of the GFR, until the renal function has stabilized. (Gadolinium
             contraindication)

          -  Enrollment in any other investigational trial for anti-arrhythmic therapy

          -  Any health related Gadolinium/MRI contraindications: Pacemaker devices, etc.

          -  Pregnant women

          -  Individuals with cognitive impairments who are unable to give informed consent

          -  Multaq® (dronedarone) contraindications:

               -  NYHA Class IV heart failure or NYHA Class II - III heart failure with a recent
                  decompensation requiring hospitalization or referral to a specialized heart
                  failure clinic

               -  Second- or third-degree atrioventricular (AV) block or sick sinus syndrome

               -  Bradycardia &lt; 50 bpm

               -  Concomitant use of strong CYP 3A inhibitors, such as ketoconazole, itraconazole,
                  voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, and
                  ritonavir

               -  Concomitant use of drugs or herbal products that prolong the QT interval and
                  might increase the risk of Torsade de Pointes, such as phenothiazine
                  anti-psychotics, tricyclic antidepressants, certain oral macrolide antibiotics,
                  and Class I and III antiarrhythmics

               -  QTc Bazett interval ≥ 500 ms or PR interval &gt; 280 ms

               -  Severe hepatic impairment

               -  Pregnant women

               -  Nursing mothers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nassir F Marrouche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <reference>
    <citation>Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999 Jan;79(1):215-62. Review.</citation>
    <PMID>9922372</PMID>
  </reference>
  <reference>
    <citation>Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F Jr, Bates ER, Lehmann MH, Vicedomini G, Augello G, Agricola E, Sala S, Santinelli V, Morady F. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med. 2006 Mar 2;354(9):934-41.</citation>
    <PMID>16510747</PMID>
  </reference>
  <reference>
    <citation>Lee SH, Tai CT, Hsieh MH, Tsai CF, Lin YK, Tsao HM, Yu WC, Huang JL, Ueng KC, Cheng JJ, Ding YA, Chen SA. Predictors of early and late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2004 Jun;10(3):221-6.</citation>
    <PMID>15133358</PMID>
  </reference>
  <reference>
    <citation>Oral H, Knight BP, Ozaydin M, Tada H, Chugh A, Hassan S, Scharf C, Lai SW, Greenstein R, Pelosi F Jr, Strickberger SA, Morady F. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol. 2002 Jul 3;40(1):100-4.</citation>
    <PMID>12103262</PMID>
  </reference>
  <reference>
    <citation>O'Donnell D, Furniss SS, Dunuwille A, Bourke JP. Delayed cure despite early recurrence after pulmonary vein isolation for atrial fibrillation. Am J Cardiol. 2003 Jan 1;91(1):83-5.</citation>
    <PMID>12505579</PMID>
  </reference>
  <reference>
    <citation>Vasamreddy CR, Lickfett L, Jayam VK, Nasir K, Bradley DJ, Eldadah Z, Dickfeld T, Berger R, Calkins H. Predictors of recurrence following catheter ablation of atrial fibrillation using an irrigated-tip ablation catheter. J Cardiovasc Electrophysiol. 2004 Jun;15(6):692-7.</citation>
    <PMID>15175066</PMID>
  </reference>
  <reference>
    <citation>Lo LW, Tai CT, Lin YJ, Chang SL, Wongcharoen W, Hsieh MH, Tuan TC, Udyavar AR, Hu YF, Chen YJ, Tsao HM, Chen SA. Mechanisms of recurrent atrial fibrillation: comparisons between segmental ostial versus circumferential pulmonary vein isolation. J Cardiovasc Electrophysiol. 2007 Aug;18(8):803-7. Epub 2007 May 14.</citation>
    <PMID>17504254</PMID>
  </reference>
  <reference>
    <citation>Pappone C, Oreto G, Rosanio S, Vicedomini G, Tocchi M, Gugliotta F, Salvati A, Dicandia C, Calabrò MP, Mazzone P, Ficarra E, Di Gioia C, Gulletta S, Nardi S, Santinelli V, Benussi S, Alfieri O. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation. 2001 Nov 20;104(21):2539-44.</citation>
    <PMID>11714647</PMID>
  </reference>
  <reference>
    <citation>Riley MJ, Marrouche NF. Ablation of atrial fibrillation. Curr Probl Cardiol. 2006 May;31(5):361-90. Review.</citation>
    <PMID>16690376</PMID>
  </reference>
  <reference>
    <citation>Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, Bash D, Schweikert R, Brachmann J, Gunther J, Gutleben K, Pisano E, Potenza D, Fanelli R, Raviele A, Themistoclakis S, Rossillo A, Bonso A, Natale A. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005 Jun 1;293(21):2634-40.</citation>
    <PMID>15928285</PMID>
  </reference>
  <reference>
    <citation>Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Fish EN, Blauer JJ, Rao SN, DiBella EV, Segerson NM, Daccarett M, Windfelder J, McGann CJ, Parker D, MacLeod RS, Marrouche NF. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009 Apr 7;119(13):1758-67. doi: 10.1161/CIRCULATIONAHA.108.811877. Epub 2009 Mar 23.</citation>
    <PMID>19307477</PMID>
  </reference>
  <reference>
    <citation>Badger TJ, Oakes RS, Daccarett M, Burgon NS, Akoum N, Fish EN, Blauer JJ, Rao SN, Adjei-Poku Y, Kholmovski EG, Vijayakumar S, Di Bella EV, MacLeod RS, Marrouche NF. Temporal left atrial lesion formation after ablation of atrial fibrillation. Heart Rhythm. 2009 Feb;6(2):161-8. doi: 10.1016/j.hrthm.2008.10.042. Epub 2008 Nov 6.</citation>
    <PMID>19187904</PMID>
  </reference>
  <reference>
    <citation>Sinha AM, Schmidt M, Marschang H, Gutleben K, Ritscher G, Brachmann J, Marrouche NF. Role of left ventricular scar and Purkinje-like potentials during mapping and ablation of ventricular fibrillation in dilated cardiomyopathy. Pacing Clin Electrophysiol. 2009 Mar;32(3):286-90. doi: 10.1111/j.1540-8159.2008.02233.x.</citation>
    <PMID>19272055</PMID>
  </reference>
  <reference>
    <citation>Badger TJ, Adjei-Poku YA, Marrouche NF. MRI in cardiac electrophysiology: the emerging role of delayed-enhancement MRI in atrial fibrillation ablation. Future Cardiol. 2009 Jan;5(1):63-70. doi: 10.2217/14796678.5.1.63. Review.</citation>
    <PMID>19371204</PMID>
  </reference>
  <reference>
    <citation>Weber KT, Weglicki WB, Simpson RU. Macro- and micronutrient dyshomeostasis in the adverse structural remodelling of myocardium. Cardiovasc Res. 2009 Feb 15;81(3):500-8. doi: 10.1093/cvr/cvn261. Epub 2008 Oct 3. Review.</citation>
    <PMID>18835843</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2010</study_first_submitted>
  <study_first_submitted_qc>August 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2010</study_first_posted>
  <results_first_submitted>September 10, 2015</results_first_submitted>
  <results_first_submitted_qc>January 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 19, 2016</results_first_posted>
  <last_update_submitted>January 22, 2016</last_update_submitted>
  <last_update_submitted_qc>January 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Nassir F. Marrouche, MD</investigator_full_name>
    <investigator_title>Associate Professor of cardiology</investigator_title>
  </responsible_party>
  <keyword>Multaq</keyword>
  <keyword>dronedarone</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Half of the patients will be assigned placebo.
dronedarone: Dronedarone will be prescribed by the patient's team according to established guidelines.</description>
        </group>
        <group group_id="P2">
          <title>Multaq® (Dronedarone)</title>
          <description>Half of the patients will be prescribed dronedarone.
dronedarone: Dronedarone will be prescribed by the patient's team according to established guidelines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Half of the patients will be assigned placebo.
dronedarone: Dronedarone will be prescribed by the patient's team according to established guidelines.</description>
        </group>
        <group group_id="B2">
          <title>Multaq® (Dronedarone)</title>
          <description>Half of the patients will be prescribed dronedarone.
dronedarone: Dronedarone will be prescribed by the patient's team according to established guidelines.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" spread="8"/>
                    <measurement group_id="B2" value="64" spread="11"/>
                    <measurement group_id="B3" value="68" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-treatment left atrial fibrosis percentage</title>
          <description>Percentage of left atrial fibrosis is determined using an MRI image of the acutal fibrotic tissue located on the surface of the left atrium. Proprietary software is used to calculate fibrosis percentage based on the image. Fibrosis percentage can range from 0% to 40%. As a rule, the higher the percentage the worse the cardiovascular outcome of the patient.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.9" spread=".10"/>
                    <measurement group_id="B2" value="15.5" spread=".05"/>
                    <measurement group_id="B3" value="17.7" spread=".08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>LA Fibrosis</title>
        <description>The change in left atrial fibrosis percentage, as measured on a scale, using MRI imaging, from baseline to the end of treatment.</description>
        <time_frame>baseline, 1 year</time_frame>
        <population>The number of participants analyzed for both groups is less than the number enrolled due to patient attrition or poor MRI scans.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Half of the patients will be assigned placebo.
dronedarone: Dronedarone will be prescribed by the patient's team according to established guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Multaq® (Dronedarone)</title>
            <description>Half of the patients will be prescribed dronedarone.
dronedarone: Dronedarone will be prescribed by the patient's team according to established guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>LA Fibrosis</title>
          <description>The change in left atrial fibrosis percentage, as measured on a scale, using MRI imaging, from baseline to the end of treatment.</description>
          <population>The number of participants analyzed for both groups is less than the number enrolled due to patient attrition or poor MRI scans.</population>
          <units>percentage of fibrosis</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread=".07"/>
                    <measurement group_id="O2" value="16.8" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Half of the patients will be assigned placebo.
dronedarone: Dronedarone will be prescribed by the patient's team according to established guidelines.</description>
        </group>
        <group group_id="E2">
          <title>Multaq® (Dronedarone)</title>
          <description>Half of the patients will be prescribed dronedarone.
dronedarone: Dronedarone will be prescribed by the patient's team according to established guidelines.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>arrhythmias</sub_title>
                <description>Includes diagnosis of AF, long QT</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>drug interactions</sub_title>
                <description>concomittant drugs interacted with Multaq</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>non compliance</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>other surgeries</sub_title>
                <description>Withdrawal due to other surgical procedures</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Manager</name_or_title>
      <organization>University of Utah</organization>
      <phone>8015873889</phone>
      <email>christina.pacchia@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

